QuidelOrtho (NASDAQ:QDEL) Shares Up 8.5% - Should You Buy?

Key Points

• QuidelOrtho shares rose 8.5% to $13.32 in Monday trading, although volume was 21% below the average session level.
• The company exceeded quarterly expectations, reporting $0.13 in EPS versus a $0.05 loss estimate and $630.9 million in revenue, up 2.8% year over year. It maintained fiscal 2026 EPS guidance of $0.65–$0.90.
• Analyst sentiment remains cautious: four analysts rate the stock “Hold” and two rate it “Sell,” producing a consensus “Reduce” rating and a $13.62 price target—close to its latest trading price.

QuidelOrtho Corporation (NASDAQ:QDEL - Get Free Report)'s share price was up 8.5% during trading on Monday . The company traded as high as $13.34 and last traded at $13.32. Approximately 1,401,162 shares changed hands during trading, a decline of 21% from the average session volume of 1,774,812 shares. The stock had previously closed at $12.28.

Analyst Ratings Changes

QDEL has been the topic of several research reports. UBS Group reiterated a "neutral" rating and issued a $12.00 price target on shares of QuidelOrtho in a report on Thursday, May 7th. Weiss Ratings restated a "sell (e+)" rating on shares of QuidelOrtho in a research note on Friday, July 17th. JPMorgan Chase & Co. upped their price objective on shares of QuidelOrtho from $11.00 to $12.00 and gave the company an "underweight" rating in a report on Wednesday, July 1st. Jefferies Financial Group reiterated a "hold" rating on shares of QuidelOrtho in a research note on Monday, June 29th. Finally, Zacks Research raised shares of QuidelOrtho from a "strong sell" rating to a "hold" rating in a report on Monday, June 15th. Four equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, QuidelOrtho has an average rating of "Reduce" and a consensus price target of $13.62.

QuidelOrtho Price Performance

The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76. The stock has a fifty day simple moving average of $15.75 and a 200-day simple moving average of $17.44. The company has a market capitalization of $920.16 million, a price-to-earnings ratio of -0.86 and a beta of 0.68.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.18. The business had revenue of $630.90 million for the quarter, compared to analysts' expectations of $618.72 million. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The business's revenue was up 2.8% on a year-over-year basis. During the same quarter last year, the company earned $0.12 EPS. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. On average, equities research analysts anticipate that QuidelOrtho Corporation will post 0.77 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QDEL. Global Retirement Partners LLC grew its position in shares of QuidelOrtho by 3,691.7% during the 4th quarter. Global Retirement Partners LLC now owns 910 shares of the company's stock valued at $26,000 after acquiring an additional 886 shares during the period. Camelot Portfolios LLC purchased a new position in QuidelOrtho during the fourth quarter worth approximately $29,000. Hantz Financial Services Inc. boosted its position in QuidelOrtho by 50.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company's stock worth $31,000 after purchasing an additional 362 shares in the last quarter. Larson Financial Group LLC grew its holdings in QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company's stock valued at $39,000 after purchasing an additional 1,015 shares during the period. Finally, GAMMA Investing LLC grew its holdings in QuidelOrtho by 67.7% in the second quarter. GAMMA Investing LLC now owns 2,185 shares of the company's stock valued at $38,000 after purchasing an additional 882 shares during the period. Hedge funds and other institutional investors own 99.00% of the company's stock.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company's product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source